TCTR20210316012CompletedPhase 4
Effects of low dose oral tolvaptan add on benefit in patients hospitalized for acute decompensated heart failure: A randomized controlled trial
/A0 sites40 target enrollmentStarted: March 16, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to N/A (No limit) (—)
- Sex
- All
Inclusion Criteria
- •1 Age more than 18 years
- •2 Acute decompensated HF
- •3 Admission within 48 hr
- •4 Plasma Na less than 145 mEq/L
- •5 Informed consent
Exclusion Criteria
- •1 Hemodynamic unstable
- •2 AKI or advanced ESRD
- •3 Severe hepatitis
- •4 Pregnancy or breastfeeding
- •5 Major surgery within 60 days
- •6 Hypersensitivity to the active substance
Investigators
Similar Trials
Completed
Not Applicable
Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertensiopulmonary hypertensionJPRN-UMIN000010196Department of Cardiology, Keio University School of Medicine40
Completed
Not Applicable
ong-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failureheart failureJPRN-UMIN000013807ihon University Surugadai Hospital100
Not yet recruiting
Phase 4
A study on the safety and efficasy of tolvaptan for patients with fluid retention after cardiothoracic surgeryPatients received cardiothoracic surgery with congestive heart failure.JPRN-UMIN000011172Osaka city university graduate school of medicine210
Completed
Not Applicable
ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease PatientsAutosomal Dominant Polycystic Kidney DiseaseJPRN-UMIN000021267Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine119
Recruiting
Not Applicable
A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.ephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneJPRN-UMIN000021708Department of Nephrology and Endocrinology, The University of Tokyo Hospital3
